MR
Merck KGaA
MRK.DE·XETRADarmstadt DEFounded 166860,000 employees
Large CappharmaPublicOncologyImmunologyNeurology
Platform: Xevinapant IAP
Market Cap
$50B
All Drugs
10
Clinical Trials
15
Failed / Terminated
5
FDA Approved
0
Stock Price & Catalysts (MRK.DE)
Loading MRK.DE stock data...
Drug Pipeline (10 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Capibrutinib | MRK-6044 | NDA/BLA | 1 | PCSK9 | Celiac | ||
| Rimasacituzumab | MRK-636 | Phase 3 | 2 | C5 | CFCLL | ||
| MRK-9679 | MRK-9679 | NDA/BLA | 1 | Menin | MesoGBM | ||
| MRK-474 | MRK-474 | Phase 3 | 1 | PCSK9 | UCGastric Ca | ||
| Datorapivir | MRK-9513 | Phase 1 | 2 | SMN2 | Melanoma | ||
| MRK-6740 | MRK-6740 | Phase 2/3 | 2 | B7-H3 | ASALS | ||
| MRK-7986 | MRK-7986 | Phase 1/2 | 2 | WRN | Ewing SarcomaADPKD | ||
| Bemavorutinib | MRK-8009 | Preclinical | 1 | PCSK9 | CKDHemophilia A | ||
| MRK-876 | MRK-876 | Preclinical | 2 | KRASG12D | MS | ||
| MRK-3890 | MRK-3890 | Phase 2 | 1 | FXIa | GBM |
SEC Filings & Financial Documents
SEC filings are not available for XETRA-listed companies.
Merck KGaA trades on XETRA (DE). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (12)